Roche’s Vabysmo (Faricimab) Receives the EC’s Approval to Treat Retinal Vein Occlusion (RVO)
Shots:
- The EC’s approval of Vabysmo for visual impairment caused by macular edema, secondary to branch/central RVO, was supported by P-III (BALATON & COMINO) studies
- The P-III studies (BALATON: n=553 & COMINO: n=729) compare Vabysmo vs aflibercept in BRVO & CRVO patients, respectively, administered with 6 monthly injections of either Vabysmo (6mg) or aflibercept (2mg) for the first 20wks., followed by Vabysmo (6mg, Q4M) with a treat-and-extend regimen at wks.24-72
- Study reached the 1EP of non-inferior visual acuity gains at 24wks., showing early & sustained vision improvement plus rapid retinal drying while 72wks. data depicted 60% (BALATON) & 48% (COMINO) of them extended the treatment to 3 or 4mos.
Ref: Roche | Image: Roche
Related News:- Roche Reports the P-III (RHONE-X) Study Data of Vabysmo for the Treatment of Diabetic Macular Edema (DME)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
